Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | INPPL1 | O15357 | 1/20 | 1.00 |
| ▸ | ALPL | P05186 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ALPI | P09923 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | ALPG | P10696 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974497 | 1.00 | KMT2A (1.00) | KMT2APKMMAPTKDM4EAPEX1 | |
| SCHEMBL28104733 | 0.88 | KMT2A (0.78) | KMT2APKMMAPTKDM4EAPEX1 | |
| SCHEMBL27974348 | 0.87 | MAPT (0.77) | KMT2APKMMAPTKDM4EAPEX1 | |
| SCHEMBL29974322 | 0.84 | PPARG (0.81) | KMT2APKMMAPTKDM4EAPEX1 | |
| SCHEMBL27221221 | 0.84 | PPARG (0.81) | KMT2APKMMAPTKDM4EAPEX1 | |
| SCHEMBL27955350 | 0.84 | PKM (0.72) | KMT2APKMMAPTKDM4EAPEX1 | |
| SCHEMBL24840880 | 0.84 | KMT2A (0.72) | KMT2APKMMAPTKDM4EAPEX1 | |
| SCHEMBL476215 | 0.84 | CBS (0.78) | KMT2APKMMAPTKDM4EAPEX1 | |
| SCHEMBL29435853 | 0.84 | CBS (0.78) | KMT2APKMMAPTKDM4EAPEX1 | |
| SCHEMBL28986431 | 0.84 | CBS (0.78) | KMT2APKMMAPTKDM4EAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302631-A1 | Inhibitors of PFKFB3 for Cancer Therapy | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2012-11-29 | — | — | US | claimed |
| US-20240347160-A1 | USE OF ARTIFICIAL INTELLIGENCE TO IDENTIFY NOVEL TARGETS AND METHODOLOGIES FOR SKIN CARE TREATMENT | KENVUE BRANDS LLC | 2024-10-17 | — | — | US | disclosed |
| US-12051491-B2 | Use of artificial intelligence to identify novel targets and methodologies for skin care treatment | JOHNSON & JOHNSON CONSUMER INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230000121-A1 | APIGENIN GLYCOSIDES FLAVOR ENHANCERS | OHIO STATE INNOVATION FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| WO-2022112439-A1 | DIAGNOSTIC METHODS FOR INFLAMMATORY DISEASE | ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) | 2022-06-02 | — | — | WO | disclosed |
| EP-3928327-A1 | USE OF ARTIFICIAL INTELLIGENCE TO IDENTIFY NOVEL TARGETS AND METHODOLOGIES FOR SKIN CARE TREATMENT | Johnson & Johnson Consumer Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| US-11136386-B2 | Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A) | PROMETHEUS BIOSCIENCES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210101988-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | CEDARS-SINAI MEDICAL CENTER | 2021-04-08 | — | — | US | disclosed |
| US-20210079473-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING SEVERE CROHN'S DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-18 | — | — | US | disclosed |
| US-20200362025-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | CEDARS-SINAI MEDICAL CENTER | 2020-11-19 | — | — | US | disclosed |
| US-20200265937-A1 | USE OF ARTIFICIAL INTELLIGENCE TO IDENTIFY NOVEL TARGETS AND METHODOLOGIES FOR SKIN CARE TREATMENT | KENVUE BRANDS LLC | 2020-08-20 | — | — | US | disclosed |
| US-9492418-B2 | Inhibitors of PFKFB3 for cancer therapy | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2016-11-15 | — | — | US | disclosed |
| US-9492418-B2 | Inhibitors of PFKFB3 for cancer therapy | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2016-11-15 | — | — | US | disclosed |
| US-9492418-B2 | Inhibitors of PFKFB3 for cancer therapy | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2016-11-15 | — | — | US | disclosed |
| US-20120302631-A1 | Inhibitors of PFKFB3 for Cancer Therapy | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2012-11-29 | — | — | US | disclosed |
| US-20120302631-A1 | Inhibitors of PFKFB3 for Cancer Therapy | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2012-11-29 | — | — | US | disclosed |
| US-20120302631-A1 | Inhibitors of PFKFB3 for Cancer Therapy | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200362025-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | KMT2A 292/4885PKM 4866/4885MAPT 3856/4885 |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | KMT2A 292/4885PKM 4866/4885MAPT 3856/4885 |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | KMT2A 292/4885PKM 4866/4885MAPT 3856/4885 |
| US-20210101988-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | KMT2A 292/4885PKM 4866/4885MAPT 3856/4885 |
| US-20120302631-A1 | Inhibitors of PFKFB3 for Cancer Therapy | PFKFB3, PFKFB2, PFKFB1 | KMT2A 853/4885PKM 35/4885MAPT 1975/4885 |
| US-11136386-B2 | Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A) | LTA, TLL1, TNF | KMT2A 1519/4885PKM 4870/4885MAPT 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.